Source author record

Nick Williams

Nick Williams appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Catalog footprint

What is connected

3works
7topics
4close collaborators

Actions

Connect this record

Log in to claim

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

3 published item(s)

preprint2026arXiv

Mechanistic Interpretability of EEG Foundation Models via Sparse Autoencoders

EEG foundation models achieve state-of-the-art clinical performance, yet the internal computations driving their predictions remain opaque: a barrier to clinical trust. We apply TopK Sparse Autoencoders (SAEs) across three architecturally distinct EEG transformers: SleepFM, REVE, and LaBraM to extract sparse feature dictionaries from their embeddings. By grounding these features in a clinical taxonomy (abnormality, age, sex, and medication), we benchmark monosemanticity and entanglement across architectures. A single hyperparameter procedure, driven by an intrinsic dictionary health audit, transfers robustly across all three architectures. Via concept steering, we introduce a "target vs. off-target" probe area metric to quantify steering selectivity and reveal three operational regimes: selectively steerable, encoded but entangled, and non-encoded. This framework exposes critical representational failures: "wrecking-ball" interventions that collapse global model performance, and clinical entanglements, such as age-pathology confounding, where it is impossible to suppress one concept without corrupting the other. Finally, a spectral decoder maps these interventions back to the amplitude spectrum, translating latent manipulations into physiologically interpretable frequency signatures, such as pathological slow-wave suppression and $α$-band restoration.

preprint2014arXiv

Conclusions from a NAIVE Bayes Operator Predicting the Medicare 2011 Transaction Data Set

Introduction: The United States Federal Government operates one of the worlds largest medical insurance programs, Medicare, to ensure payment for clinical services for the elderly, illegal aliens and those without the ability to pay for their care directly. This paper evaluates the Medicare 2011 Transaction Data Set which details the transfer of funds from Medicare to private and public clinical care facilities for specific clinical services for the operational year 2011. Methods: Data mining was conducted to establish the relationships between reported and computed transaction values in the data set to better understand the drivers of Medicare transactions at a programmatic level. Results: The models averaged 88 for average model accuracy and 38 for average Kappa during training. Some reported classes are highly independent from the available data as their predictability remains stable regardless of redaction of supporting and contradictory evidence. DRG or procedure type appears to be unpredictable from the available financial transaction values. Conclusions: Overlay hypotheses such as charges being driven by the volume served or DRG being related to charges or payments is readily false in this analysis despite 28 million Americans being billed through Medicare in 2011 and the program distributing over 70 billion in this transaction set alone. It may be impossible to predict the dependencies and data structures the payer of last resort without data from payers of first and second resort. Political concerns about Medicare would be better served focusing on these first and second order payer systems as what Medicare costs is not dependent on Medicare itself.

preprint2013arXiv

An Exploratory Data Survey of Drug Name Incidence and Prevalence From the FDA's Adverse Event Reporting System, 2004 to 2012Q2

Drug Names, Population Level Surveillance and the FDA's Adverse Event Reporting System: An Exploratory Data Survey of Drug Name Incidence and Prevalence, 2004-2012Q2 Purpose: To count and monitor the drug names reported in the publicly available version of the Federal Adverse Event Reporting System (FAERS) from 2004 to 2012Q2 in a maximized sensitivity relational model. Methods: Data mining and data modeling was conducted and event based summary statistics with plots were created from over nine continuous years of continuous FAERS data. Results: This FAERS model contains 344,452 individual drug names and 432,541,994 count references which occurred across 4,148,761 human subjects in the 34 quarter study period. Plots for the top 100 scoring drug name references are reported by year and quarter; the top 100 drug names contain 143,384,240 references or 33% of all drug name references over 34 quarters of continuous FAERS data. Conclusions: While FAERS contains many drugs and adverse event reports, its data pertains to very few of them. Drug name incidence lends timely and effective surveillance of large populations of Averse Event Reports and does not require the cause of the AE, nor its validity to be known to detect a mass poisoning.